The mission of the American Association for Cancer Research is to prevent and cure cancer at the earliest possible time, utilizing all mechanisms at its disposal to further progress against cancer. We are now at an important juncture in the evolution of cancer and biomedical research. Along with these remarkable advances comes a weighty responsibility. How can we take advantage of the best that cancer science has to offer? How can we exploit the wealth of genomics and other relevant data? How can we promote the translation of new scientific discoveries into real and sustained benefits for cancer patients? And how can we accelerate these advances in cancer research?
To address these pressing questions, the leadership of the AACR felt that its mission could be effectively strengthened by the formation of the Council of Scientific Advisors (CSA). The members of the Council are elected by the Board of Directors and report directly to the Board.
The Association has an important role to fill in fostering cancer research, science policy, and scientific communication. The CSA, with its top leaders from all aspects of cancer and biomedical research, will have enormous impact in the form of expert advice and counsel on matters that affect the cancer research community. The CSA is an important new AACR entity of the highest priority and its recommendations will have overarching implications, both nationally and internationally.
George F. Vande Woude, Ph.D., Chairperson
VARI Director and Distinguished Scientific Investigator
Van Andel Research Institute
Grand Rapids, MI
James P. Allison, Ph.D.
Chairman, Immunology Program
Howard Hughes Medical Institute Investigator
Memorial Sloan-Kettering Cancer Center
New York, NY
José Baselga, M.D.
Chairman and Professor of Medicine, Medical Oncology Service
Vall d'Hebron University Hospital
Barcelona, Spain
Anton J. M. Berns, Ph.D.
Director of Research and Group Leader, Molecular Genetics
The Netherlands Cancer Institute
Amsterdam, Netherlands
J. Michael Bishop, M.D.
Chancellor and Distinguished Professor
University of California, San Francisco
San Francisco, CA
Nancy Brinker
Founder
Susan G. Komen Breast Cancer Foundation
Dallas, TX
Joan S. Brugge, Ph.D.
Chair, Department of Cell Biology
Harvard Medical School
Boston, MA
Ronald M. Evans, Ph.D.
Professor of Biology
Howard Hughes Medical Institute Investigator
The Salk Institute for Biological Studies
La Jolla, CA
Napoleone Ferrara, M.D.
Staff Scientist, Department of Molecular Oncology
Genentech, Inc.
South San Francisco, CA
Waun Ki Hong, M.D.
Professor and Head, Division of Cancer Medicine
UT M. D. Anderson Cancer Center
Houston, TX
Susan Band Horwitz, Ph.D.
Distinguished Professor, Departments of Molecular Pharmacology and Cell Biology
Albert Einstein College of Medicine
Bronx, NY
Sherry Lansing
CEO
Sherry Lansing Foundation
Los Angeles, CA
Theodore S. Lawrence, M.D., Ph.D.
Professor and Chair, Department of Radiation Oncology
University of Michigan
Ann Arbor, MI
Arnold J. Levine, Ph.D.
Systems Biology Professor
Institute for Advanced Study
Princeton, NJ
Edison T. Liu, Ph.D.
Executive Director
Genome Institute of Singapore
Singapore
Cecil B. Pickett, Ph.D.
President, Research and Development
Biogen Idec
Cambridge, MA
Janet D. Rowley, M.D.
Blum-Riese Professor
University of Chicago Medical Center
Chicago, IL
Phillip A. Sharp, Ph.D.
Institute Professor
MIT Center for Cancer Research
Cambridge, MA
Ellen V. Sigal, Ph.D.
Chairperson
Friends of Cancer Research
Arlington, VA
Margaret R. Spitz, M.D.
Professor and Chair, Department of Epidemiology
UT M. D. Anderson Cancer Center
Houston, TX
Craig B. Thompson, M.D.
Director, Abramson Cancer Center
University of Pennsylvania
Philadelphia, PA
Daniel D. Von Hoff, M.D.
Director, Clinical Translational Research Division
TGen
Phoenix, AZ
Karen H. Vousden, Ph.D.
Director
Beatson Institute for Cancer Research
Glasgow, Scotland
Irving L. Weissman, M.D.
Professor, Departments of Pathology, Developmental Biology, and Biological Sciences
Stanford University Medical Center
Palo Alto, CA